Skip to main content

Table 1 Cohorts’ clinical characteristics and rs2304166 genotypes’ distribution

From: GP6 rs2304166 polymorphism is associated with response to natalizumab in multiple sclerosis patients

Criteria Natalizumab Responsive Natalizumab Unresponsive
Exome cohort n = 23 n = 10
 Sex (Female/male) 14 / 9 9 / 1
 MS type (RRMS/SPMS) 19 / 4 6 / 4
 Age at natalizumab treatment (Average years) 32.3 32.5
 Duration of natalizumab treatment (Average years) 2.95 3
 EDSSa before/after natalizumab [Median (IQRb)] 3 (2–4.5) / 3 (2–4) 3.5 (2.5–6) / 6 (4.5–6.5)
GP6 rs2304166 genotypes
  GG 7 0
  GC 12 3
  CC 4 7
Replicate cohort n = 67 n = 19 p-value
 Sex (Female/male) 36 / 31 16 / 3 0.018
 MS type (RRMS/SPMS) 56 / 11 13 / 6 0.19
 Age at natalizumab treatment (Average years) 32.8 34.5 0.09
 Duration of natalizumab treatment (Average years) 3.17 3.25 0.66
 EDSSa before/after natalizumab [Median (IQRb)] 2.5 (2–4) / 2 (1.5–3) 4.25 (2–6) / 6.5 (5.5–7) < 0.001
GP6 rs2304166 genotypes
  GG 20 1 0.0000027
  GC 37 4  
  CC 10 14  
  1. aEDSS Expanded disability status scale, bIQR Interquartile range